About Acer Therapeutics
Acer Therapeutics is a company based in Cambridge (United States) founded in 1991 by Chris Schelling was acquired by Zevra in November 2023. The company has 37 employees as of December 31, 2022. Acer Therapeutics has completed 1 acquisition, including Opexa Therapeutics. Acer Therapeutics offers products and services including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities. Acer Therapeutics operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 37 as on 31 Dec, 2022
- Founders Chris Schelling
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acer Therapeutics
Acer Therapeutics offers a comprehensive portfolio of products and services, including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.
Treatment for Maple Syrup Urine Disease conditions
Investigational treatment for Vascular Ehlers-Danlos Syndrome
Explores new therapies for ultra-rare diseases
People of Acer Therapeutics
Unlock access to complete
Funding Insights of Acer Therapeutics
Investors in Acer Therapeutics
Acer Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zevra and TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in life science innovations for healthcare transformation.
|
Locked | Locked | Locked | |
|
Marketing services are provided to biopharma companies.
|
Locked | Locked | Locked |
Investor details for Acer Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acer Therapeutics
Acer Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opexa Therapeutics.
Investment portfolio details for Acer Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Acer Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Acer Therapeutics
Detailed financials for Acer Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acer Therapeutics Comparisons
Peer comparison for Acer Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acer Therapeutics
Acer Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
Detailed competitors of Acer Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acer Therapeutics
Complete news archive for Acer Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acer Therapeutics
Acer Therapeutics was founded in 1991 and raised its 1st funding round 24 years after it was founded.
Acer Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Chris Schelling is the current CEO of Acer Therapeutics. They have also founded this company.
As of Dec 31, 2022, the latest employee count at Acer Therapeutics is 37.
Annual revenue of Acer Therapeutics is $1.26M as on Dec 31, 2021.
Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.
Acer Therapeutics's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Acer Therapeutics offers OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.
Acer Therapeutics has made 1 acquisition, including Opexa Therapeutics.
Acer Therapeutics has 2 investors. Key investors include Zevra, and TVM Capital Life Science.